AsPac dermatologists get support from pharma firm

MANILA, Philippines - Global pharmaceutical commercialization services company Invida has expressed its full support for dermatologists in the Asia-Pacific region by launching the Invida Skin Science range of high-quality, clinically proven skin care brands for scar treatment, wound healing and skin aging.

“We are privileged to support skin care experts in the region with our comprehensive range of clinically proven safe and effective dermatological products,” said Dr. Maaliddin Biruar, medical and scientific affairs director of Invida Philippines.

Invida launched its Skin Science range during a media roundtable discussion organized in connection with the 20th Regional Conference of Dermatology (RCD) held recently at the Edsa Shangri-La Hotel in Mandaluyong City.

First held in 1972, the biennial RCD aims to maintain the highest professional standards for dermatologists within the region and foster cooperation among members of the different national dermatological societies in Southeast Asia and Australia.

“This collegial gathering of respected skin care experts in the Asia-Pacific region is the perfect venue to launch our range of science-based skin care products,” said Ninia Torres, country head of Invida Philippines.

The Invida Skin Science is a range of skin therapeutic and aesthetic products that are prescribed by dermatologists, plastic surgeons and obstetricians.

It includes Atopiclair, a steroid-free, preservative-free and scent-free emollient cream for the treatment of mild to moderate atopic dermatitis; Dermatix Ultra, a transparent, fast-drying silicone gel with advanced scar treatment formula; Kinerase, an anti-aging cosmeceutical containing the plant growth factor kinetin for the treatment of fine lines, wrinkles, skin texture and blotchiness; Papulex, a specially formulated line of products that keeps acne-prone skin in good condition through its cleansing, treating and protecting action; and other products for the treatment of skin infections and glabellar lines.     

“Various clinical studies show that Papulex is an effective and safe treatment for acne. Nicotinamide (the active ingredient of Papulex) has no photoallergic and phototoxic effects, making Papulex safe to use even in summertime,” said professor Stefano Veraldi, past president of the Italian Acne Board and secretary of the Associazione Lombarda di Dermatologia e Venereologia.

“Clinical trials have shown that kinetin (the active ingredient of Kinerase) can delay and even reverse the effects of aging in human skin cells,” said Dr. Priya Sen, consultant dermatologist and laser surgeon of the National Skin Center, Singapore.

Veraldi and Sen were among the distinguished speakers in the RCD. Both experts also shared their expert insights during the media roundtable discussion.

Invida was formed in 2005 by a powerful strategic partnership among Quintiles, the world’s leading pharmaceutical services organization; Temasek Holdings, one of the world’s largest investment companies; and Zuellig Group, the largest pharmaceutical distribution and supply chain management network in the Asia-Pacific.

With more than 3,500 employees in 13 Asia-Pacific countries, Invida aims to become the leading provider of important health care brands and services to improve the lives of people in the region.

Invida partners with emerging and multinational biopharmaceutical companies to commercialize differentiated pharmaceutical products of superior quality.

In November 2011, the Florence-based Italian multinational company Menarini Group completed its acquisition of Invida.

Menarini is the leading Italian pharmaceutical group in the world and ranks 15th among 4,881 companies in Europe and 34th among 14,051 companies in the world.

With 12,890 employees and operating in more than 100 countries, Menarini caters to the needs of patients and physicians in the following therapeutic fields: cardiology, gastroenterology, infectious disease, pulmonology, and endocrinology.